Coupa Software Jumps on Strong EPS, UiPath Falls By Investing.com

After-Hours Stock Movers:

UiPath Inc. (PATH) 16% LOWER; reported Q2 EPS of ($0.02), $0.09 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $242.2 million versus the consensus estimate of $230.64 million. UiPath Inc. sees Q3 2023 revenue of $243-245 million, versus the consensus of $269.6 million. UiPath Inc. sees FY2023 revenue of $1.002-1.007 billion, versus the consensus of $1.09 billion.

Coupa Software (NASDAQ:) 13% HIGHER; reported Q2 EPS of $0.20, $0.11 better than the analyst estimate of $0.09. Revenue for the quarter came in at $211 million versus the consensus estimate of $203.83 million. Announces Board of Directors Authorized $100 Million Share Repurchase Program. Coupa Software sees Q3 2023 EPS of $0.08-$0.10, versus the consensus of $0.06. Coupa Software sees Q3 2023 revenue of $211-214 million, versus the consensus of $214 million. Coupa Software sees FY2023 EPS of $0.37-$0.44, versus the consensus of $0.26. Coupa Software sees FY2023 revenue of $838-844 million, versus the consensus of $840.3 million.

Aquestive Therapeutics (NASDAQ:) 10% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $8.50.

Crescent Energy Company (CRGY) 6% LOWER; announced the commencement of an underwritten public offering of 5,000,000 shares of its Class A common stock,

Eledon Pharmaceuticals, Inc. (ELDN) 6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

Newell Brands (NWL) 3% LOWER; warns for Q3 and FY. The company sees Q3 net sales of $2.21-$2.32 billion, versus prior guidance of $2.39-$2.5 billion and the consensus of $2.52 billion. The company sees EPS of $0.46-$0.51, versus prior of $0.50-$0.54, and the consensus of $0.53. The company sees FY net sales of $9.37-$9.58 billion, versus prior guidance of $9.76-$9.98 billion and the consensus of $9.89 billion. The company sees FY EPS of $1.56-$1.70, versus prior guidance of $1.79-$1.86 and the consensus of $1.84.

Paycor HCM, Inc. (Nasdaq: PYCR) 3% LOWER; announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP.

Guidewire Software (NYSE:) 2% HIGHER; reported Q4 EPS of $0.03, $0.04 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $244.6 million versus the consensus estimate of $229.57 million. Guidewire Software sees Q1 2023 revenue of $190-195 million, versus the consensus of $187.7 million. Guidewire Software sees FY2023 revenue of $885-895 million, versus the consensus of $882 million.

Medpace Holdings (NASDAQ:) 2% HIGHER; CEO, August Troendle via Medpace Investors, LLC, bought 90,790 shares from 09/01/22-09/02/22 at prices from $144.52-$144.98, bringing the firm’s stake to 5,604,429 shares. Troendle also owns 806,643 shares directly.

Harley-Davidson (NYSE:) 1.3% HIGHER; President/CEO, Jochen Zeitz, bought 25,750 shares on 09/02/22 at $38.94. The value of the purchase was over $1 billion.